Clinical Trials on Fallopian Tube Carcinoma

Total 24027 results

ARCAGY/ GINECO GROUP

Completed

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

France
Volastra Therapeutics, Inc.

Recruiting

A Study of Sovilnesib in Subjects With Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary | Chromosomal Instability

United States
National Cancer Institute (NCI)

Completed

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

Peritoneal Neoplasms | Fallopian Tube Cancer | Epithelial Ovarian Cancer

United States
pharmaand GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
AA Secord
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynecologic Neoplasms | Uterine Endometrial Cancer

United States
New Mexico Cancer Care Alliance

Active, not recruiting

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Mersana Therapeutics
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Terminated

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer

United States, Australia, Canada
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Advanced Solid Tumor With Evidence of Germline or Somatic BRCA

United States, Israel, Spain, Canada, United Kingdom
Mersana Therapeutics

Recruiting

A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer | Adenoid Cystic Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Shanghai Gynecologic Oncology Group
Shanghai Zhongshan Hospital

Unknown

Total/Subtotal Colectomy in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Secondary Malignant Neoplasm of Large Intestine

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Epithelial Cancer

United States
Western Regional Medical Center

Terminated

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma (PGA)

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Numab Therapeutics AG

Terminated

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Colorectal Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Peritoneal Carcinoma | Head and Neck Squamous Cell Carcinoma | Ovarian Carcinoma | Squamous Cell Carcinoma

United States, Taiwan, Spain
Charite University, Berlin, Germany
Kliniken Essen-Mitte

Recruiting

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer (KORE)

Fallopian Tube Cancer | Frailty | Ovary Cancer | Peritoneum Cancer

Germany
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute; New York University Cancer Institute

Completed

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University Health Network, Toronto

Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Endometrioid Tumor | TP53 Mutation

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Translational Research Center for Medical Innovation...
Japanese Gynecologic Oncology Group (JGOG); Department of Obstetrics and Gynecology... and other collaborators

Completed

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
National Cancer Institute (NCI)

Completed

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States
Janssen Research & Development, LLC
PharmaMar

Completed

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Poland, United Kingdom, China, Switzerland, Israel, South Africa, Australia, Russian Federation, New Zealand
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive...

Completed

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Canada
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Sarcoma | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

United States
University of Minnesota

Terminated

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Constipation | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Bowel Obstruction

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Sanofi; Genentech, Inc.

Completed

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

United States
Medical University Innsbruck

Unknown

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Austria
Korean Gynecologic Oncology Group

Unknown

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Recruiting

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Terminated

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Endometrioid Tumor | Malignant Ovarian Serous Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Malignant... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Translational Research Center for Medical Innovation...
Okayama University; Japanese Gynecologic Oncology Group (JGOG)

Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | BRCA1 and/or BRCA2 Variant Carriers

Japan
Seoul National University Hospital
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (SELENIUM)

Ovarian Cancer | Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Chemotherapy-induced Peripheral Neuropathy | Primary Peritoneal Carcinoma

Korea, Republic of
AbbVie

Completed

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Breast Cancer | Hepatocellular Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Melanoma | Primary Peritoneal Cancer | Non-hematologic Malignancies
Kancera AB
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Recruiting

A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (KANDOVA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Denmark, Norway, Sweden
Tesaro, Inc.
Merck Sharp & Dohme LLC

Completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

Neoplasms | Breast Cancer | Advanced Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Peritoneal Cancer | Stage IV Breast Cancer

United States
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Sutro Biopharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Korea, Republic of, Israel, Singapore, Canada
University of Pennsylvania
National Institutes of Health (NIH); Tmunity Therapeutics, a wholly owned subsidiary...

Active, not recruiting

CAR T Cells in Mesothelin Expressing Cancers

Ovarian Cancer | Fallopian Tube Cancer | Lung Adenocarcinoma | Peritoneal Carcinoma | Mesotheliomas Pleural | Mesothelioma Peritoneum

United States
National Cancer Institute (NCI)

Terminated

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Fallopian Tube Cancer | Recurrent Ovarian Epithelial Cancer | Malignant Tumor of Peritoneum

United States

Clinical Trials on Fallopian Tube Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations